Key points are not available for this paper at this time.
The role of host defense in cancer is highly variable. Although there are cases where spontaneous cures of cancer appear to be mediated by immunologic mechanisms, malignant disease generally progresses even in patients where tumor-specific immunity can be demonstrated. It is apparent that there are complex interactions between tumor cells and dendritic cells, the dominant antigen-presenting cells of the immune system. Through their inhibitory actions upon dendritic cells, tumor cells can negatively regulate priming of tumor-specific immunity. Recent work has also shown that dendritic cells have direct cytotoxic effects upon tumor cells. These interactions may impact on the efficacy of current strategies using dendritic cell-based vaccines for tumor immunotherapy.
Cho et al. (Tue,) studied this question.